Skip to main content
CSL Ltd. logo

CSL Ltd. — Investor Relations & Filings

Ticker · CSL ISIN · AU000000CSL8 LEI · 529900ECSECK5ZDQTE14 ASX Manufacturing
Open in API
Filings indexed 2,557 across all filing types
Latest filing 2008-02-03 Regulatory Filings
Country AU Australia
Listing ASX CSL

About CSL Ltd.

https://www.csl.com/

CSL is a global biotechnology company that researches, develops, manufactures, and markets a diverse portfolio of medicines. The company operates through distinct business units. CSL Behring provides plasma-derived and recombinant biotherapies for patients with rare and serious diseases, including bleeding disorders, immunodeficiencies, and neurological disorders. CSL Seqirus is a leading provider of vaccines, with a focus on influenza prevention and public health. CSL Vifor specializes in therapies for iron deficiency and nephrology, addressing the full spectrum of kidney disease. Collectively, CSL delivers lifesaving and life-enhancing treatments to a global patient population.

Recent filings

Filing Released Lang Actions
AAH: Arana Achieves Milestone in Collaboration with CSL 2 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a press release announcing a milestone achievement in a collaboration between Arana Therapeutics and CSL. It discusses the successful completion of a project phase, triggering a milestone payment, and potential future payments and royalties. There are no financial statements, regulatory form references, or detailed financial data. The content is an update on a business development or partnership milestone rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or business update. Given the lack of a more specific category, the fallback category Regulatory Filings (RNS) is appropriate with high confidence.
2008-02-03 English
Change in substantial holding 19 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604 Corporations Act 2001 Section 671B' and is a 'Notice of Change of Interests of Substantial Holder' addressed to CSL Limited. It details changes in voting power and securities holdings of a substantial shareholder (FMR Corp and FIL) over various dates in 2007. The content focuses on reporting changes in share ownership and voting rights, consistent with regulatory requirements for substantial shareholding notifications. There is no indication of financial results, management commentary, or other report types. This matches the definition of a Major Shareholding Notification (MRQ). The document length is substantial and contains detailed transaction data, confirming it is the notification itself, not an announcement of a report or a certification. Therefore, the correct classification is MRQ with high confidence.
2008-01-23 English
Appendix 3B 8 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is addressed to ASX Limited's Company Announcements Office. Appendix 3B is a standard form used in Australian securities regulation for announcing new issues of securities, applications for quotation of additional securities, and related agreements. The content includes details about the class of securities issued (ordinary shares), number of securities, terms, and other issuance details. There is no financial performance data, management discussion, or audit information. The document is a regulatory announcement about capital changes, specifically a new issue of shares and related securities. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed issuance information, confirming it is not a mere announcement of a report but a formal filing about capital changes.
2008-01-07 English
CSL Research and Development Briefing 53 pages ?Kb
Board/Management Information Classification · 90% confidence The document is a detailed R&D briefing from December 2007, focusing on research and development activities, product pipelines, clinical trials, and scientific data related to vaccines, plasma products, and recombinant proteins. It includes extensive scientific and strategic information about the company's R&D efforts, product development stages, and clinical studies. There is no indication that this is an annual or interim financial report, audit report, earnings release, or any regulatory filing. It is not a presentation for investors or a call transcript, nor does it announce voting results, capital changes, or legal proceedings. The content is clearly focused on management-level information about R&D strategy and progress, which fits best under Board/Management Information (MANG) as it relates to senior management's strategic briefing on R&D.
2007-12-12 English
Appendix 3B 7 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares by CSL Limited, including the number of shares issued, issue price, purpose, and quotation application to the ASX. It follows the format of an Appendix 3B form, which is a standard regulatory filing used in Australia to announce new securities issues and apply for their quotation on the stock exchange. The document does not contain financial statements or management discussion but is focused on the announcement of a capital raising event and related securities issuance details. Therefore, it fits the category of a Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication notice, but a substantive regulatory filing about new share issuance.
2007-12-12 English
Change of Directors Interests 12 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including the number of shares held before and after the change, dates of changes, and consideration paid. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements, earnings data, or management discussion, but rather reports insider share transactions by directors. Therefore, it fits the definition of 'Director's Dealing' filings.
2007-12-02 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.